Fabior

Quick links to important sections

Fabior

Selected form

Treatment option: Zits, Acne Vulgaris

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fabior

Property Description
Active ingredient Tazarotene
Form Topical Foam (Aqueous-Based Emulsion)
Pharmacological class Retinoid (Acetylenic Class), Topical Acne Agent
General purpose Regulates cell turnover and reduces inflammation
Origin Synthetic Prodrug

What Type of Medicine is Fabior? (Identity and Classification)

Fabior is a specific brand-name, prescription-only, topical pharmaceutical whose active component is the synthetic compound tazarotene, a third-generation retinoid. Tazarotene belongs to the acetylenic class of retinoids, chemically related to Vitamin A, placing the medicine in the pharmacological categories of a Topical Acne Agent and a Topical Antipsoriatic. This classification is clinically recognized for its potent activity in modulating skin conditions. Tazarotene functions as a prodrug; it is chemically inactive until it is absorbed by the skin and converts into its biologically effective form, tazarotenic acid.

Composition and Form: The Aqueous-Based Foam Vehicle

The medicine is specifically formulated as a topical foam, an aqueous-based emulsion foam designed for direct application to the skin. This dosage form is a primary differentiating feature of the Fabior brand, contrasting with earlier gel or cream tazarotene preparations. The vehicle is engineered to be ethanol-free and preservative-free, utilizing a water and light mineral oil base, which creates a rapidly absorbed preparation that supports effective drug delivery into the skin, often preferred by patients for its lightweight feel.

General Purpose of Tazarotene

The essential function of tazarotenic acid is to manage skin conditions by regulating fundamental cellular processes, such as the growth and shedding of skin cells. The compound functions as a highly specific retinoid receptor agonist. As a powerful retinoid, its general purpose is to normalize excessive keratinocyte proliferation while also exhibiting the ability to reduce localized skin inflammation. This dual action profile addresses underlying biological factors, promoting healthier skin structure and appearance, typical of regimens designed for skin maintenance.

Regulatory References

  1. NIH Research

What side effects are possible with Fabior?

Possible Side Effects and Safety Information

Adverse reactions to this medicine are primarily categorized in regulatory documents as local skin reactions occurring at the application site. These effects fall within the Skin and Subcutaneous Tissue Disorders category. The most frequently documented reactions are classified as Common (occurring in 6% or more of patients in clinical trials) and include application site irritation (14%), dryness (7%), erythema (redness) (6%), and exfoliation (peeling) (6%). Other reactions, such as application site pain, photosensitivity, pruritus (itching), and dermatitis, are documented as Uncommon (1-5%).

Official labeling specifies that the intensity of these local reactions is often observed to peak during the second week of treatment and generally tends to lessen with continued use.

Population-Specific Safety Constraints

The most critical safety constraint is the potential for fetal harm, which makes the medicine contraindicated during pregnancy. Tazarotene is a known teratogen. Regulatory requirements for females of childbearing potential mandate obtaining a negative pregnancy test prior to starting treatment and using an effective method of contraception throughout therapy.

Safety-Related Restrictions

Official documents include restrictions regarding use on abraded or eczematous skin due to the risk of severe local irritation. Due to heightened susceptibility to burning, exposure to sunlight or UV lamps must be avoided, and caution is advised regarding weather extremes like wind and cold. Furthermore, the foam vehicle contains a propellant that is flammable, and patients must avoid fire, flame, and smoking during and immediately following application.

This safety profile is structured by regulatory bodies to communicate both the high frequency of expected, transient local effects and the absolute necessity of adhering to the major constraint regarding teratogenicity.

Overdose and Emergency Response

The regulatory overdose profile for Fabior (Tazarotene Topical Foam) differentiates between localized reactions from excessive use and the risk associated with accidental systemic exposure.

Localized Overdose Manifestations

Overdose resulting from excessive topical application is defined by local manifestations at the application site. Documented clinical signs include the development of marked redness, peeling, and severe skin discomfort. The management specified for this localized overdose response involves the discontinuation of the product until skin integrity returns to normal or a reduction in the frequency of application.

Systemic Exposure and Emergency Action

A distinct and more severe scenario is an overdose resulting from the accidental oral ingestion of the foam. This systemic route of exposure is the circumstance explicitly associated with the risk of serious or life-threatening symptoms, such as collapsing or developing trouble breathing.

Official regulatory guidance mandates immediate emergency actions for this type of exposure. If accidental ingestion has occurred, contacting a poison control center is required. Furthermore, immediate medical help must be sought by calling local emergency services (e.g., 911) if the victim exhibits serious systemic distress, such as collapsing or not breathing. The regulatory documentation does not specify the existence of a known antidote or unique population-specific monitoring requirements.

Therapeutic Uses of Fabior

What Fabior Treats: Main Uses and Benefits

Treatment of Acne Symptom Clusters

The medication is commonly used to support the management of acne vulgaris in adolescents and adults. It is relevant for easing challenging symptoms associated with both the non-inflammatory symptom clusters, such as blackheads and whiteheads, and the inflammatory symptom clusters, including papules and pustules. It is typically applied in conditions marked by heightened symptoms, such as moderate-to-severe presentations, and is used in areas where short-term symptom management is appropriate. This treatment provides support that helps ease the overall symptom burden, contributing to improved comfort during symptomatic periods.

Supportive Management for Recurrent and Widespread Symptoms

Fabior is considered relevant in clinical settings for the management of recurrent acne and is often used during phases when symptoms become more noticeable. The vehicle supports the application across domains where additional symptomatic support is needed, which is useful when groups of symptoms cluster across widespread surface areas, including the face or trunk. This contributes to easing the overall symptom load during symptomatic phases and helps maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Relief for Inflammatory or Irritative States


Eligibility and Restrictions for Use

The eligibility for using Fabior (tazarotene) topical foam is strictly defined by regulatory documents, focusing primarily on reproductive status, age, and existing skin conditions.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adolescents and Adults aged 12 years or older.
Populations for whom use is not recommended Children younger than 12 years of age (safety/efficacy not established).
Populations for whom use is contraindicated Individuals who are Pregnant or those with a known Hypersensitivity to any component.

Eligibility-Related Restrictions

Fabior is contraindicated in pregnancy, as tazarotene is a retinoid with known teratogenic risk. Females of child-bearing potential must obtain a negative pregnancy test within two weeks before starting therapy and must use an effective method of contraception throughout treatment.

The medicine must not be used on irritated skin, including areas affected by sunburn, abrasions, or eczema. While using the medication, patients must exercise caution regarding sun exposure and extreme weather. Use in older adults is limited, as clinical trials did not include sufficient data for this population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Fabior (tazarotene topical foam) establishes interaction patterns primarily related to pharmacodynamic augmentation and chemical degradation risks with specific co-administered substances. The prescribing information confirms that no formal drug-drug interaction studies were conducted regarding metabolic pathways, such as CYP enzymes.

Documented Pharmacodynamic and Chemical Interactions

Interaction Type Interacting Substance/Class Official Interaction Outcome or Restriction
Cumulative Irritant Risk Concomitant topical acne therapy or dermatologic products with a strong drying effect May result in a cumulative irritant effect. Products with a strong drying effect should be avoided.
Augmented Photosensitivity Systemic photosensitizers (e.g., tetracyclines, thiazides, sulfonamides) Increased possibility of augmented photosensitivity. Co-administration requires caution.
Chemical Degradation Oxidizing agents (e.g., benzoyl peroxide) May cause degradation of tazarotene and reduce clinical efficacy. Must be applied at different times of the day.

Official pharmacokinetic studies specifically assessed the combination of tazarotene with combination oral contraceptives (norethindrone and ethinyl estradiol) and confirmed that co-administration did not affect the systemic exposure of the contraceptive components. There are no documented interactions with food, alcohol, or specific herbal products in the official prescribing information.

Mechanism of Action

How Fabior Works: Mechanism of Action

Fabior is a targeted small molecule designed to modulate activity within defined biological pathways. Its mechanistic profile results from its primary action as an antagonist (or inhibitor) that directly engages key receptor or enzyme systems located within target cells.

This initial molecular interaction modifies the primary biological signal. Fabior's engagement leads to the modification of specific molecular cascades associated with increased pathway activation. It acts to suppress signaling sequences driven by dominant transmitters or mediators, thereby modulating pathway regulation within the cell. This targeted interference in key regulatory systems influences the activity of physiological responses. By contributing to a modulated state within the affected pathways and reducing the activity of excessive mediator signaling, Fabior initiates specific intracellular consequences that result in corresponding systemic physiological adjustments.

Dosage and Administration Information

Official Administration Guidelines

The use of Fabior (tazarotene) topical foam, 0.1%, involves precise methods for application and scheduling. The official route of administration is topical use only on the skin; the product is explicitly not intended for oral, ophthalmic, or intravaginal application.

Labeled Dosing and Frequency The medicine is applied once daily in the evening. The regimen specifies applying a thin layer of the foam, using only enough to lightly cover the entire affected area, typically the face and/or upper trunk. For patients 12 years of age and older, this frequency is standard. If a dose is missed, the standard protocol is to skip that dose and continue with the regular schedule the following evening. A typical course of use may be associated with a duration of up to 12 weeks.

Preparation and Procedural Structure The application protocol requires specific steps to ensure correct delivery. The skin must be fully dried after cleansing with a mild wash before application. The foam is dispensed into the palm and then applied using the fingertips, gently massaging the product into the skin until it disappears. Users must wash their hands immediately after application. A special procedural note advises avoiding fire, flame, and smoking during and immediately following application, due to the foam vehicle’s properties. The frequency may be reduced or temporarily interrupted as a means to manage the continuation of the course.


Instruction Classifications (High-Level)

Administration Method Frequency Pattern Use-Context Constraints
Topical Once Daily Application to clean, dry skin; use in the evening; avoidance of fire/flame.

Recent Clinical Evidence

Research evidence / Overview of Studies for Fabior

Evidence for Use in Acne Vulgaris (Moderate-to-Severe)

Research exploring Fabior was evaluated in primary short-term, large-scale, randomized controlled trials (RCTs). These pivotal studies were evaluated in individuals aged 12 and older with moderate-to-severe acne vulgaris. Researchers used a specific study design where the active tazarotene foam was observed in comparison against a non-medicated, or vehicle, foam. This approach was used to identify the apparent patterns observed in the active group compared to the non-medicated preparation.

The studies research examined various ways of monitoring symptom variability over time. These included tracking the total count of both non-inflammatory and inflammatory lesions. Reports described that the patients receiving the active foam were associated with different measurements in outcomes, such as lesion counts and Investigator's Global Assessment (IGA) scores, compared to those receiving the non-medicated vehicle foam. Separate studies also monitored the systemic absorption of the drug, and research describes that the active ingredient in the bloodstream was observed in the studies.

Comparison of the Foam Formulation to Other Vehicles

Studies explored how the unique foam formulation was evaluated in comparison with older, established forms of tazarotene, such as gels or creams. These were primarily pharmacokinetic (PK) studies, which research examined the temporary physiological balance of the drug in the body. The research explored patterns related to absorption, and studies reported that the exposure of the active ingredient in the bloodstream was observed in the studies, which was noted to align with the measurements reported for the older gel formulation.

Study Duration and Long-Term Follow-up

The primary evidence base for Fabior was derived from studies monitoring responses over defined time intervals, with the main efficacy trials having a maximum follow-up duration of 12 weeks. This focus means that the research primarily evaluated temporary symptom changes. As a result, there is limited information for long-term outcomes beyond the initial study period. The long-term effects are not fully established.

What Remains Uncertain in the Research Landscape

One key limitation is that the large, pivotal trials were vehicle-controlled; comparative evidence is lacking against other active topical acne treatments. Furthermore, the follow-up durations were limited to 12 weeks, meaning the certainty remains low regarding the long-term evolution of symptoms. The results apply only to the populations studied, and data for certain groups remain insufficient outside of the studied cohorts.

Frequently Asked Questions (FAQ)

Common questions about Fabior (FAQ)


Q: How quickly does Fabior typically start clearing up acne?

Official clinical studies for Fabior foam tracked changes in acne symptoms, such as lesion counts, over a maximum of 12 weeks. While results may vary for each person, this period reflects the general timeframe over which the medication's effects were monitored in clinical trials.


Q: Does Fabior cause an initial 'purging' phase, and if so, how long does it last?

Regulatory information notes that common local skin reactions, such as irritation, dryness, and redness, are frequently experienced. These local effects were often reported to peak during the second week of treatment in clinical trials, though they generally tended to lessen with continued use.


Q: Can I use Fabior with other over-the-counter acne washes or treatments?

Official documents advise that products with a strong drying effect, as well as certain other topical acne therapies, should be avoided when using Fabior. This is because combining these products may result in a severe cumulative irritant effect on the skin.


Q: Are there any specific cleansers or moisturizers recommended while using Fabior?

Because dryness is a common side effect, a moisturizer is often used. However, while official usage instructions recommend applying the medicine to clean, dry skin, regulatory information does not recommend specific commercial brands or products.


Q: Should I apply sunscreen every day while on Fabior, even indoors?

The official warnings state that patients using Fabior should wear sunscreen daily and take other protective measures against sun exposure. This is due to the potential for photosensitivity, which is a heightened susceptibility to severe sunburn and skin damage.


Q: Does Fabior interact with common oral antibiotics for acne?

Official information advises caution when using Fabior with systemic photosensitizers, which are medications that increase light sensitivity. This group includes tetracyclines, a common class of oral antibiotics for acne, due to the increased possibility of augmented photosensitivity.


Q: What types of cosmetics or makeup should I avoid while using Fabior?

The official documentation cautions against using other skin care products that may cause irritation. This includes products that are harsh, dry out the skin, or contain ingredients such as alcohol, spices, astringents, or lime, which may aggravate irritation.


Q: How long after stopping Fabior is it safe to become pregnant?

Fabior is contraindicated in pregnancy and official documents require effective contraception throughout the entire treatment period. However, the regulatory label does not specify a required period to wait, often called a 'washout period,' after treatment cessation.


Q: Can I use Fabior with laser treatments or chemical peels?

Official instructions advise that Fabior must not be used on irritated, abraded, or eczematous skin. Patients should also avoid procedures like cryodestruction or chemodestruction (types of peels) for a period before and during use to minimize irritation risk.


Q: Can Fabior cause hyperpigmentation or skin darkening in certain skin tones?

While the official side effect list includes irritation and erythema (redness), it does not specifically list hyperpigmentation (skin darkening) as a common side effect. Clinical trial data suggests the foam was effective in all studied racial subgroups.


Q: What is the difference between Fabior and generic tazarotene creams?

Fabior is a specific brand-name tazarotene topical foam, 0.1% concentration, indicated for moderate-to-severe acne. Other formulations of tazarotene, such as creams or gels, are also available, including generic versions.


Q: How does Fabior compare to other common prescription acne gels like tretinoin or adapalene?

The primary clinical studies for Fabior were conducted against a non-medicated vehicle foam, not against other active topical treatments. Because of this, official regulatory documents state that comparative evidence against other acne treatments is currently lacking.


Q: Can Fabior be used to treat body acne, like on the back or chest?

Yes, the medication is officially indicated for topical use on acne vulgaris on the face and/or the upper trunk. The upper trunk includes areas such as the chest and shoulders.


Q: Is Fabior used for treating acne scars or just active breakouts?

Fabior is officially approved for the topical treatment of acne vulgaris (active breakouts) in patients 12 years and older. Its approved purpose is to address active acne, not acne scarring.


Q: Why do some people say Fabior is stronger than other retinoids?

The active ingredient in Fabior, tazarotene, functions as a retinoid receptor agonist. The compound shows high selectivity for certain retinoid receptors, which contributes to its therapeutic activity.


Q: Are headaches a known side effect of Fabior?

Official adverse reaction data for Fabior foam primarily lists local skin effects at the application site, such as irritation, dryness, and redness. Headaches are not listed as a common or uncommon adverse reaction in the product's regulatory label.


Q: Can Fabior be used on skin conditions other than acne?

The specific formulation of Fabior topical foam is officially approved by regulatory bodies only for the treatment of acne vulgaris. Other formulations of the active ingredient tazarotene are approved for different conditions, such as psoriasis.


Q: Does using more Fabior than directed make it work faster?

Official guidance warns that applying more medicine or using it more often than directed is not expected to speed up the results. Using the medication excessively may instead increase the risk of skin irritation.


Q: What kind of studies have been done on the long-term effects of Fabior?

The main regulatory evidence for Fabior is based on clinical studies with a maximum follow-up duration of 12 weeks. Because of this limited monitoring period, the official documents state that information regarding long-term outcomes beyond 12 weeks is limited.


Q: Is it okay to put Fabior on if I have a small cut or abrasion on my face?

Official warnings state that the medicine must not be applied to irritated skin. This includes areas affected by cuts, abrasions, sunburn, or eczema, as applying the medication to broken skin can increase the risk of severe local irritation.


Q: Can Fabior cause allergic reactions, and what are the signs?

Fabior is contraindicated (should not be used) in individuals who have a known hypersensitivity to any of its components. While severe skin irritation is a common side effect, the official label does not specifically detail the signs of a systemic allergic reaction.


Q: What happens if I accidentally get Fabior in my eyes or mouth?

Fabior is for topical use only, and contact with the eyes, mouth, nostrils, and mucous membranes must be avoided. If contact occurs, the regulatory instructions state that the affected area should be rinsed well with water.


Q: Is there a difference in strength between the different Fabior concentrations?

Fabior topical foam is currently only manufactured and sold at a single strength: 0.1% concentration. Other brands or generic forms of the active ingredient, tazarotene, may be available in different concentrations, such as a 0.05% strength.


Q: Can men use Fabior just as effectively as women?

The official regulatory documents indicate that the pivotal clinical trials for Fabior included both male and female participants ranging in age from 12 to 45 years. Efficacy and tolerability were evaluated across both male and female participants in the clinical trials.


Q: Does the foam version of Fabior absorb better than a gel or cream?

Official pharmacokinetic studies, which measure drug absorption, compared the foam to the older gel formulation. These studies reported that the systemic exposure of the active ingredient in the bloodstream was lower for the foam formulation than it was for the gel.


Q: Does Fabior interact with any common herbal supplements?

The official prescribing information for Fabior specifically states that there are no documented interactions with specific herbal products. Similarly, there are no documented interactions with food or alcohol.


Q: Are there specific food or drink interactions to be aware of while using Fabior?

According to the official prescribing information, there are no specific documented interactions with any food or drink products. The document also states that there are no documented interactions with alcohol or specific herbal products.


Q: Is Fabior less effective for cystic or nodular acne?

Fabior foam is officially indicated for the treatment of moderate-to-severe acne. Clinical trial protocols typically involve patients with inflammatory lesions, but clinical trials for the product were generally not designed to assess use in individuals with severe nodulocystic acne.


Q: How should I apply Fabior to ensure the whole affected area is covered?

Official usage instructions recommend applying the medication as a thin layer, lightly covering the entire affected area, and then gently massaging the product into the skin until it disappears.


Q: Is Fabior ever used for anti-aging purposes?

The specific product, Fabior topical foam, is officially approved by the FDA only for the treatment of acne vulgaris. However, the active ingredient, tazarotene, is approved in other formulations for treating sun-damaged skin, including fine wrinkles and mottled hyperpigmentation.


Q: What if the Fabior foam doesn't feel like it's spreading easily?

The application protocol instructs users to dispense the foam into the palm and then apply it using the fingertips. The product should be gently massaged into the skin until it disappears.


Q: Does alcohol consumption affect the safety or efficacy of Fabior?

The official prescribing information confirms that there are no documented interactions with alcohol. The document also states that there are no documented interactions with food or specific herbal products.

How should Fabior be stored and disposed of?

How to Store and Dispose of Fabior?

Storage and disposal requirements for Fabior (tazarotene) topical foam are officially mandated to ensure stability and safety, particularly due to the product's pressurized, flammable nature.

Mandatory Storage Conditions

Requirement Specifics
Temperature Store at controlled room temperature: 20 C to 25 C (68 F to 77 F).
Prohibited Conditions Do not freeze. Keep the can away from fire and direct heat.
Handling Store the canister upright and avoid spraying near fire or flame.
Child Safety Must be kept out of the sight and reach of children.

Disposal Requirements

The propellant in Fabior is classified as flammable. Due to this, the official instructions strictly prohibit puncturing the can or throwing it into a fire, even when empty. Patients are advised to consult a healthcare professional regarding the proper disposal method for any unused or expired medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fabior found in:

A-Z Index: